Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China

Table 3

Stratification analysis of genotypes and risk of PCa conducted by age, BMI, and SBP.

	AA (case/Control)	AB (case/Control)	BB (case/Control)	AB + BB (case/Control)	P1	OR1 (95% CI)	P2	OR2 (95% CI)	P3	OR3 (95% CI)
rs16944	GG	AG	AA	AG + AA
Age	24/27	40/79
≤70	6/21	20/55	7/21	27/176	0.650	1.273 (0.499, 3.607)	0.808	1.167 (0.335, 4.060)	0.671	1.243 (0.454–3.407)
>70	18/6	20/24	19/13	39/137	0.019	0.287 (0.093, 0.833)	0.222	0.487 (0.152, 1.558)	0.041	0.351 (0.126–0.982)
BMI
≤23	3/8	10/30	8/9	18/39	1.000	0.889 (0.197, 4.014)	0.515	2.370(0.463, 12.138)	1.000	1.231 (0.292–5.193)
>23	21/19	30/49	18/25	48/74	0.130	0.559 (0.257, 1.195)	0.332	0.651 (0.274, 1.551)	0.144	0.587 (0.286, 1.205)
SBP
<140	12/17	20/40	13/14	33/54	0.458	0.708 (0.284, 1.766)	0.611	1.315 (0.457, 3.783)	0.741	0.866 (0.368, 2.039)
≥140	12/10	20/39	13/30	33/59	0.091	0.427 (0.158, 1.159)	0.269	0.542 (0.182, 1.614)	0.107	0.466 (0.182, 1.195)
rs2070874	TT	TC	CC	TC + CC
Age	55/89	34/46	1/5	35/51
≤70	23/58	10/36	1/3	11/39	0.411	0.700 (0.299, 1.640)	1.000	0.841 (0.083, 8.503)	0.417	0.711 (0.312, 1.623)
>70	32/31	24/10	0/2	24/12	0.060	2.325 (0.957, 5.649)	0.492	2.032 (.581, 2.612)	0.125	1.938 (0.827, 4.537)
BMI
≤23	16/32	4/14	0/1	20/25	0.233	1.597 (0.738, 3.456)	1.000	1.522 (1.285, 1.802)	0.274	1.533(0.712, 3.304)
>23	39/57	30/32	1/4	15/26	0.764	0.833 (0.391, 1.992)	0.621	0.347 (0.037, 3.256)	0.578	0.800 (0.365, 1.755)
SBP
<140	24/46	20/24	0/1	20/25	0.233	1.597 (0.738, 3.456)	1.000	1.522 (1.285, 1.802)	0.274	1.533 (0.712, 3.304)
≥140	31/43	14/22	1/4	15/26	0.764	0.883 (0.391, 1.992)	0.621	0.347 (0.037, 3.256)	0.578	0.800(0.365, 1.755)
rs2227284	TT	TG	GG	TG + GG
Age	69/100	20/39	1/1
≤70	29/66	4/30	1/1	5/31	0.031	0.303 (0.098, 0.940)	0.525	2.276 (0.138, 37.651)	0.052	0.367 (0.130, 1.039)
>70	40/34	16/9	0/0	16/9	0.386	1.511 (0.593, 3.853)	—	—	0.386	1.511 (0.593, 3.853)
BMI
≤23	17/37	3/9	0/1	3/10	0.925	0.725 (0.174, 3.023)	1.000	1.459 (1.218, 1.749)	0.797	0.653 (0.159, 2.680)
>23	52/63	17/30	1/0	18/30	0.291	0.687(0.341, 1.381)	0.457	2.212(1.809, 2.704)	0.364	0.727(0.365, 1.450)
SBP
<140	35/54	9/17	0/0	9/17	0.664	0.817 (0.328, 2.035)	—	—	0.664	0.817 (0.328, 2.035)
≥140	34/46	11/22	1/1	12/23	0.365	0.676 (0.290, 1.581)	1.000	1.353 (0.082, 22.406)	0.408	0.706 (0.309, 1.614)
rs7175701	TT	TC	CC	TC + CC
Age	88/131	2/9
≤70	31/193	1/4	0/0	¼	1.000	0.750 (0.081, 6.966)	—	—	—	—
>70	57/138	1/5	0/0	1/5	0.098	0.133 (0.015, 1.187)	—	—	—	—
BMI
≤23	20/45	0/2	0/0	0/2	1.000	1.444 (1.228, 1.699)	—	—	—	—
>23	68/86	2/7	0/0	2/7	0.334	0.361 (0.073, 1.796)	—	—	—	—
SBP
<140	43/67	2/4	0/0	2/4	1.000	0.779 (0.137, 4.439)	—	—	—	—
≥140	45/64	0/5	0/0	0/5	0.168	1.703 (1.155, 1.993)	—	—	—	—
rs11556218	TT	TG	GG	TG + GG
Age	66/87	20/48	4/5
≤70	24/63	9/31	0/3	9/34	0.544	0.762 (0.317, 1.835)	0.562	1.381 (1.213–1.572)	0.412	0.695 (0.270–1.662)
>70	42/24	11/17	4/2	15/19	0.029	0.370 (0.149–0.918)	1.000	1.143 (0.195–6.709)	0.062	0.451 (0.194–1.048)
BMI
≤23	15/32	4/15	1/0	5/15	0.378	0.569 (0.161–2.010)	0.269	6.290 (0.242–163.426)	0.571	0.711 (0.218–2.322)
>23	5/55	16/33	3/5	19/38	0.071	0.523 (0.258–1.062)	0.822	0.647 (0.147–2.846)	0.069	0.539 (0.276, 1.053)
SBP
<140	34/45	8/23	3/3	11/26	0.094	0.460 (0.184–1.155)	1.000	1.324 (0.251–6.969)	0.170	0.560 (0.243–1.289)
≥140	32/42	12/25	1/2	13/27	0.272	0.630 (0.275–1.442)	1.000	0.656 (0.057–7.560)	0.263	0.632 (0.282–1.415)

Notes: P1, OR1: comparison between AB vs. AA; P2, OR2: comparison between BB vs. AA; P3, OR3: comparison between AB + BB vs. AA. PCa, prostate cancer; BMI, body mass index; SBP, systolic blood pressure.